

	<p>the possibility of bypassing the lengthy development process typically required for new drugs, moving directly to preclinical testing and clinical trials, which reduces both risk and costs (Guangxu et al. 2014).</p>	
<p>Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators (2010b) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. <i>New England J Med</i> 363(25):2487–2498. https://doi.org/10.1056/NEJMoa1007907</p> <p>Lemoine P, Guilleminault C, Alvarez E (2007) Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. <i>J Clin Psychiatry</i> 68(11):1723–1732. https://doi.org/10.4088/JCP.v68n1112</p>	<p>02123-3</p> <p>Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators (2010b) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. <i>N Engl J Med</i> 363(26):2487–2498. https://doi.org/10.1056/NEJMoa1006885</p> <p>Lauenroth VD, Stargardt T (2017) Pharmaceutical pricing in Germany: how is value determined within the scope of AMNOG? <i>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</i> 20(7):927–935. https://doi.org/10.1016/j.jval.2017.04.006</p> <p>Lemoine P, Guilleminault C, Alvarez E (2007) Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. <i>J Clin Psychiatry</i> 68(11):1723–1732. https://doi.org/10.4088/JCP.v68n1112</p> <p>New added (not in text!)</p>	
<p>Luppa PB, Zeller M, Pieper M, Kaiser P, Weiss N, Vierbaum L, Freckmann G (2024) Quality assessment of glucose measurement with regard to epidemiology and clinical management of diabetes mellitus in Germany. <i>Front Mol Biosci</i>. https://doi.org/10.3389/fmolb.2024.1371426</p> <p>Mathias M, Susanne K, De Bruin ML, Torbjörn C, Sukhwinder J, Hallgreen CE (2019) The effectiveness of direct to healthcare professional communication - a systematic review of communication factor studies. <i>Res Soc Adm Pharm</i> 15(5):475–482. https://doi.org/10.1016/j.sapharm.2018.06.015</p> <p>Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C, on behalf of the ATLAS ACS-TIMI 46 study group (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>The Lancet</i> 374(9683):29–38.</p>	<p>Luppa PB, Zeller M, Pieper M, Kaiser P, Weiss N, Vierbaum L, Freckmann G (2024) Quality assessment of glucose measurement with regard to epidemiology and clinical management of diabetes mellitus in Germany. <i>Front Mol Biosci</i>. https://doi.org/10.3389/fmolb.2024.1371426</p> <p>Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. <i>Nat Rev Drug Discov</i> 9(3):203–214. https://doi.org/10.1038/nrd3078</p> <p>Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 study group (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet (London, England)</i> 374(9683):29–38.</p> <p>New added (not in text)</p>	
<p>358(24):2433–2446. https://doi.org/10.1056/NEJMoa0802748</p> <p>Peinemann F, Labeit A (2019) Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: a study based on federal joint committee data. <i>J Evidence-Based Med</i> 12(1):9–15. https://doi.org/10.1111/jebm.12340</p> <p>Piening S, Reber KC, Wieringa JE, Straus SMJM, de Pieter PA, Haaijer-Ruskamp FM, Mol PGM (2012) Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. <i>Clin Pharmacol Ther</i> 91(5):838–845. https://doi.org/10.1038/CLPT.2011.308</p> <p>Polaris Observatory HCV Collaborators (2022) Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>Lancet Gastroenterol Hepatol</i> 7(5):396–415. https://doi.org/10.1016/S2468-1253(21)00472-6</p>	<p>244b. https://doi.org/10.1056/NEJMoa0708579</p> <p>Peinemann F, Labeit A (2019) Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data. <i>J Evid-Based Med</i> 12(1):9–15. https://doi.org/10.1111/jebm.12340</p> <p>Polaris Observatory HCV Collaborators (2022) Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>Lancet Gastroenterol Hepatol</i> 7(5):396–415. https://doi.org/10.1016/S2468-1253(21)00472-6</p> <p>New added (not in text)</p>	<p>https://doi.org/10.1056/NEJMoa1010494</p> <p>Robert Koch Institute (2024) Epidemiological bulletin 28/2024: estimate of the number of new HIV infections in 2022 and 2023 and the total number of people living with HIV in Germany by the end of 2023. Retrieved from https://www.rki.de/EN/News/Publications/Epidemiologisches-Bulletin/HIV-Epid-Bull-28-2024.pdf?__blob=publicationFile&v=2</p> <p>Piening S, Reber KC, Wieringa JE, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, Mol PG (2012) Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands.</p> <p>moved</p>